BRIEF-GSK gets European regulators approval for biotech asthma drug
Reuters Sept 24 GlaxoSmithkline Plc. * Receives positive CHMP opinion in Europe for novel anti-IL5 biological nucala for treatment of patients with severe refractory eosinophilic asthma. * Decision is based on results from clinical study programme, which … |
View full post on asthma – Google News